Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia
- PMID: 15599467
Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia
Abstract
Stenotrophomonas maltophilia is an important nosocomial pathogen with intrinsic multi-drug resistance. This retrospective study reviewed 84 episodes of S. maltophilia bacteremia over a 4-year period from July 1999 to September 2003. Stenotrophomonas maltophilia bacteremia was hospital-acquired in 64 patients (76%), and developed after prolonged hospitalization in 48 (57%). Seventy patients (83%) had a central venous catheter (CVC), 64 (76%) had prior antibiotic therapy, 55 (65%) had underlying malignancy, and 43 (51%) were receiving immunosuppressive therapy. Twenty seven percent of the episodes of bacteremia had polymicrobial isolates. The overall and bacteremia-related mortality rates were 44% and 33%, respectively. Forty six percent of the bacteremia-related mortality occurred within 3 days after onset of symptoms. The most common sources of bacteremia were respiratory tract (33%) and CVC (31%), while the source of the bacteremia was unknown in 26% of episodes. The most effective antibiotics in vitro were trimethoprim-sulfamethoxazole, ciprofloxacin, chloramphenicol, and ceftazidime; however, a trend of increasing drug resistance in these agents was identified over the study period. On univariate analysis, nosocomial bacteremia, long-lasting neutropnenia (>10 days), bacteremia originating from the respiratory tract, shock, low serum albumin level (<3 g/dL), and thrombocytopenia (platelet count <100,000/mm3) were significantly related to mortality (p<0.05). Among these variables, shock and thrombocytopenia were independent factors associated with mortality. In contrast, patients with CVC-related bacteremia had a lower mortality rate (odds ratio, 0.04; p<0.001). Patients treated with appropriate antibiotics had a lower mortality rate, but this difference was not significant (p=0.477). In S. maltophilia bacteremia, careful evaluation of CVC was important for identifying the source of bacteremia and predicting prognosis. The source of bacteremia and condition of patients at presentation were the major factors influencing prognosis.
Similar articles
-
Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.J Microbiol Immunol Infect. 2016 Jun;49(3):378-86. doi: 10.1016/j.jmii.2014.06.005. Epub 2014 Jul 28. J Microbiol Immunol Infect. 2016. PMID: 25081988
-
Stenotrophomonas maltophilia bacteremia in pediatric patients-- a 10-year analysis.J Microbiol Immunol Infect. 2006 Apr;39(2):144-9. J Microbiol Immunol Infect. 2006. PMID: 16604247
-
Clinical aspects and risk factors of nosocomial Stenotrophomonas maltophilia bacteremia episodes in a Turkish intensive care unit.J Chemother. 2007 Dec;19(6):658-64. doi: 10.1179/joc.2007.19.6.658. J Chemother. 2007. PMID: 18230546
-
Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.Clin Microbiol Infect. 2019 May;25(5):546-554. doi: 10.1016/j.cmi.2018.11.008. Epub 2018 Nov 16. Clin Microbiol Infect. 2019. PMID: 30448331
-
Optimizing therapy for Stenotrophomonas maltophilia.Semin Respir Crit Care Med. 2007 Dec;28(6):672-7. doi: 10.1055/s-2007-996414. Semin Respir Crit Care Med. 2007. PMID: 18095231 Review.
Cited by
-
Stenotrophomonas maltophilia Infections in Pediatric Patients - Experience at a European Center for Pediatric Hematology and Oncology.Front Oncol. 2021 Oct 12;11:752037. doi: 10.3389/fonc.2021.752037. eCollection 2021. Front Oncol. 2021. PMID: 34712613 Free PMC article.
-
A review of 11 years of Stenotrophomonas maltophilia blood isolates at a tertiary care institute in Canada.Can J Infect Dis Med Microbiol. 2012 Winter;23(4):165-9. doi: 10.1155/2012/762571. Can J Infect Dis Med Microbiol. 2012. PMID: 24294268 Free PMC article.
-
A Systemic Lupus Erythematosus Patient With Febrile Neutropenia Developing After Intraocular Administration of Bevacizumab.Arch Rheumatol. 2016 Jan 28;31(2):176-179. doi: 10.5606/ArchRheumatol.2016.5747. eCollection 2016 Jun. Arch Rheumatol. 2016. PMID: 29900958 Free PMC article.
-
Stenotrophomonas maltophilia Infections in Adults: Primary Bacteremia and Pneumonia.Jundishapur J Microbiol. 2015 Aug 22;8(8):e23569. doi: 10.5812/jjm.23569. eCollection 2015 Aug. Jundishapur J Microbiol. 2015. PMID: 26468367 Free PMC article.
-
Clinical ineffectiveness of latamoxef for Stenotrophomonas maltophilia infection.Infect Drug Resist. 2015 Oct 20;8:353-7. doi: 10.2147/IDR.S90726. eCollection 2015. Infect Drug Resist. 2015. PMID: 26527890 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical